Axinn Advises McKesson in Securing Controlling Interest in Core Ventures

Axinn is pleased to represent McKesson Corporation (NYSE: MCK), a leading, diversified health care services company, as lead antitrust counsel on its acquisition of a controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures) for approximately $2.49 billion in cash, which will represent approximately 70% ownership. Announced on August 26, the Core Ventures transaction is part of McKesson’s efforts to advance community-based oncology care, seeking to bring advanced treatments and improved outcomes to patients, while also reducing the overall cost of care. Core Ventures was established by Florida Cancer Specialists (FCS), a leading physician-owned community oncology practice, and Core Ventures serves as its exclusive provider of non-clinical business and other administrative services. FCS will join McKesson’s The U.S. Oncology Network, a leading oncology organization, dedicated to advancing local and affordable cancer care and better patient outcomes.

The Axinn antitrust team is led by partners Jeny Maier and Daniel Bitton, and assisted by counsel Carol Liu and Michael O'Mara.

About Axinn

Axinn combines the skills, experience, and dedication of the world’s largest firms with the focus, responsiveness, efficiency, and attention to client needs of the best boutiques. The firm was established in the late 1990s by lawyers from premier Wall Street firms with a common vision: provide the highest level of service and strategic acumen in antitrust, intellectual property, and high-stakes litigation. Axinn’s lawyers have served as lead or co-lead counsel on more than half a trillion dollars in transactions and, in the last 10 years alone, have handled more than 500 litigations.